These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10215361)

  • 21. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivastigmine in the treatment of alcohol-induced persisting dementia.
    Gibson RC; Barnaby L
    West Indian Med J; 2003 Mar; 52(1):59-61. PubMed ID: 12806761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
    Bentham P; Gray R; Sellwood E; Raftery J
    BMJ; 1999 Sep; 319(7210):640-1. PubMed ID: 10473490
    [No Abstract]   [Full Text] [Related]  

  • 24. Guidelines for managing Alzheimer's disease: Part II. Treatment.
    Cummings JL; Frank JC; Cherry D; Kohatsu ND; Kemp B; Hewett L; Mittman B
    Am Fam Physician; 2002 Jun; 65(12):2525-34. PubMed ID: 12086242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
    Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
    Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholinesterase inhibitors: expanding applications.
    Cummings JL
    Lancet; 2000 Dec; 356(9247):2024-5. PubMed ID: 11145482
    [No Abstract]   [Full Text] [Related]  

  • 27. Surprising discovery with Alzheimer's medication.
    Thacker PD
    Drug Discov Today; 2003 May; 8(9):379-80. PubMed ID: 12706648
    [No Abstract]   [Full Text] [Related]  

  • 28. [Mechanisms of action of Alzheimer medications].
    Alhainen K
    Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
    Bianchetti A; Rozzini R; Trabucchi M
    Curr Med Res Opin; 2003; 19(4):350-3. PubMed ID: 12841930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
    McMillan H
    Int J Geriatr Psychiatry; 1999 Dec; 14(12):1078-9. PubMed ID: 10607978
    [No Abstract]   [Full Text] [Related]  

  • 31. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Linkins KW; Lloyd JR; Hjelmstad GO; Strausbaugh HJ
    Pharmacoeconomics; 2000 Dec; 18(6):609-12. PubMed ID: 11227398
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug treatment for Alzheimer's disease.
    Freyne A; Cooney C
    Ir Med J; 1999; 92(7):424-5. PubMed ID: 10967863
    [No Abstract]   [Full Text] [Related]  

  • 33. Featured CME topic: dementia. Medication update.
    Slagle MA
    South Med J; 2001 Jul; 94(7):678-81. PubMed ID: 11531174
    [No Abstract]   [Full Text] [Related]  

  • 34. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].
    Dartigues JF; Goulley F; Bourdeix I; Péré JJ; Barberger-Gateau P
    Rev Neurol (Paris); 2002 Sep; 158(8-9):807-12. PubMed ID: 12386525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's disease: translating neurochemical insights into clinical benefits.
    J Clin Psychiatry; 2000 Oct; 61(10):791-802. PubMed ID: 11078045
    [No Abstract]   [Full Text] [Related]  

  • 37. Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.
    Blais L; Kettani FZ; Perreault S; Leroux JC; Forget A; Kergoat MJ
    J Am Geriatr Soc; 2009 Feb; 57(2):366-8. PubMed ID: 19207161
    [No Abstract]   [Full Text] [Related]  

  • 38. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical treatment of Alzheimer's disease: past, present, and future.
    Ott BR
    Med Health R I; 2002 Jul; 85(7):210-2. PubMed ID: 12182092
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.